In the ongoing human effort to outmaneuver cancer's defenses, a Chinese clinical trial has offered a quietly significant finding: a two-drug combination targeting the HER2 protein from both inside and outside the cell achieved complete tumor elimination in 60% of women with advanced breast cancer before surgery. The neoPICD trial, conducted across seven centers in China, enrolled 108 evaluable patients and produced response rates that rival or exceed some current global standards. While the absence of a direct comparison group tempers certainty, the results invite a deeper question about wheth
Dual HER2-Targeted Combo Achieves 60% Pathologic Response in Advanced Breast Cancer
Attack HER2 from two directions at once—outside and inside the cell.
Mark
Why does attacking HER2 from two different angles matter more than just using one drug?
Mimi
Because cancer cells are clever. If you only block the receptor from outside, some cells find ways to signal through it anyway. By also shutting down the internal machinery, you're closing off escape routes. It's harder for the tumor to adapt.
Mark
The response rates are higher than the standard treatment. But you said the trial has no comparison group. How do we know this is actually better?
Mimi
We don't, not yet. That's the honest answer. The numbers look good on their own, but without a head-to-head trial, we're comparing apples to slightly different apples. The next step is the randomized trial.
Mark
The hormone receptor-negative tumors responded much better than the hormone receptor-positive ones. What does that tell us?
Mimi
It tells us these drugs work best in a specific population. If you're a woman with hormone receptor-negative, HER2-positive breast cancer, this combination might be particularly valuable for you. For hormone receptor-positive disease, the benefit is real but smaller.
Mark
Diarrhea in 73% of patients sounds like a lot. How do you manage that?
Mimi
It is a lot, but most cases were mild to moderate. Doctors have ways to handle it—dietary changes, medications. The real question is whether patients can tolerate it for six months of treatment. That's something the next trial will need to watch closely.
Mark
These drugs aren't approved in the U.S. yet. What happens now?
Mimi
The Chinese team is planning a larger randomized trial. If that works, they'll likely seek regulatory approval. But Western oncologists will want to see how it compares to what they're already using. That comparison trial is the key.
Il Polso
- HER2-positive breast cancer remains a formidable adversary — even the best current therapies leave a substantial portion of patients with residual disease and elevated recurrence risk.
- The neoPICD trial's 60.2% pathologic complete response rate and 100% disease control across 108 patients signal that this dual-targeting strategy is producing real, measurable disruption of tumor biology.
- A sharp divide in outcomes between hormone receptor-negative (73.3% response) and hormone receptor-positive (43.8% response) patients suggests the combination's power is unevenly distributed — and that smarter patient selection could sharpen its impact.
- Diarrhea affected nearly three-quarters of patients, and sixteen withdrew from the trial, raising honest questions about whether the regimen's efficacy comes at a tolerable human cost.
- Without a randomized comparison arm, the trial cannot yet prove superiority over trastuzumab and pertuzumab — the global benchmark — leaving clinicians in a posture of cautious optimism rather than confident adoption.
- A planned phase III randomized trial will be the true test, determining whether this Chinese-developed regimen can earn a place in the global standard of care or remains a promising regional signal.
In the ongoing human effort to outmaneuver cancer's defenses, a Chinese clinical trial has offered a quietly significant finding: a two-drug combination targeting the HER2 protein from both inside and outside the cell achieved complete tumor elimination in 60% of women with advanced breast cancer before surgery. The neoPICD trial, conducted across seven centers in China, enrolled 108 evaluable patients and produced response rates that rival or exceed some current global standards. While the absence of a direct comparison group tempers certainty, the results invite a deeper question about whether attacking a single biological target from multiple angles simultaneously may represent a more complete therapeutic logic.
A clinical trial in China has produced notable results in the treatment of locally advanced HER2-positive breast cancer, pairing two drugs — inetetamab and pyrotinib — that attack the same molecular target through different mechanisms. Inetetamab blocks the HER2 receptor from outside the cell; pyrotinib silences its signaling from within. Together with standard chemotherapy, this four-drug regimen was given to patients before surgery across seven Chinese medical centers.
Of the 108 patients who completed the neoadjuvant phase, 60.2% achieved pathologic complete response — meaning no invasive cancer remained in the breast or lymph nodes at the time of surgery. Nearly all patients showed meaningful tumor shrinkage, and every patient achieved at least disease control. Both drugs were developed in China and have not received FDA approval, but their combined performance places them within — and in some respects above — the range produced by trastuzumab and pertuzumab, the current international standard.
Tumor biology shaped outcomes significantly. Patients with hormone receptor-negative disease responded at a rate of 73.3%, while those with hormone receptor-positive tumors responded at 43.8%. Multivariable analysis confirmed that hormone receptor status and the highest level of HER2 expression were independent predictors of benefit — findings that could guide future patient selection.
Safety was broadly manageable, with no treatment-related deaths. Diarrhea was common, affecting nearly three-quarters of participants, though severe cases were infrequent. Sixteen patients did not complete the protocol — six due to adverse effects, ten due to noncompliance.
The trial's central limitation is its single-arm design: without a concurrent comparison group, it cannot definitively establish superiority over existing therapies. Follow-up at a median of 22.9 months is also relatively brief for drawing conclusions about long-term survival. Senior breast oncologist Dr. Rebecca Alexandra Dent described the findings as promising while emphasizing that randomized trials — including comparisons with newer agents like trastuzumab deruxtecan — will be necessary before this approach can be widely adopted. The research team has announced plans for a larger phase III trial to answer those remaining questions.
A two-drug combination targeting HER2 from different angles has produced striking results in women with advanced breast cancer in China. In a phase II trial called neoPICD, researchers gave 108 patients with locally advanced HER2-positive breast cancer a regimen pairing inetetamab, a monoclonal antibody, with pyrotinib, a tyrosine kinase inhibitor, alongside standard chemotherapy before surgery. The approach achieved a 60.2% pathologic complete response rate—meaning no invasive cancer remained in the breast or lymph nodes after treatment—with 92.6% of patients showing significant tumor shrinkage and all patients achieving disease control.
The strategy rests on a simple but elegant idea: attack HER2 from two directions at once. Inetetamab blocks the receptor from outside the cell, while pyrotinib shuts down its signaling from within. Both drugs were developed in China and are not yet approved by the U.S. Food and Drug Administration. The combination was tested because standard neoadjuvant therapy using trastuzumab and pertuzumab, the current global benchmark, produces pathologic complete response rates between 45% and 68%—leaving a substantial portion of patients without complete tumor elimination and at higher risk of recurrence.
The trial enrolled 124 patients across seven centers in China with stage II or III HER2-positive breast cancer and significant tumor burden. Of those, 108 completed the neoadjuvant phase and were analyzed. Patients received six cycles of the four-drug regimen every three weeks, then underwent surgery two to four weeks later. Treatment continued for a full year after surgery. The median age was 52 years. About 83% had the highest level of HER2 expression, and roughly half had hormone receptor-negative disease—a subgroup that historically responds better to HER2-targeted therapy.
Response rates varied meaningfully by tumor biology. Among patients with hormone receptor-negative cancers, the pathologic complete response rate reached 73.3%, compared to 43.8% in those with hormone receptor-positive disease. This difference suggests that patient selection—identifying which women are most likely to benefit—could be crucial for future use. Multivariable analysis confirmed that hormone receptor-negative status and the highest level of HER2 expression independently predicted better outcomes.
Safety was generally manageable. No treatment-related deaths occurred. Diarrhea was the most common side effect, affecting 73% of patients, though severe diarrhea was uncommon. Other toxicities—anemia, nausea, loss of appetite—aligned with what clinicians expect from chemotherapy and HER2-targeted drugs. Sixteen patients discontinued treatment: six due to adverse events and ten due to noncompliance.
The trial has clear limitations. It was single-arm, meaning there was no direct comparison group receiving standard therapy, making it impossible to know whether this combination truly outperforms trastuzumab and pertuzumab. Follow-up was relatively short at a median of 22.9 months, and longer-term survival data remain immature. The high rate of diarrhea, while manageable, raises questions about quality of life during treatment.
Dr. Rebecca Alexandra Dent, a senior breast cancer specialist at Singapore's National Cancer Centre, called the results "promising" but cautioned that randomized trials comparing this approach to current standards—including the newer drug trastuzumab deruxtecan—will be essential before widespread adoption. The investigators plan a larger phase III randomized trial and longer-term follow-up to measure survival outcomes and better understand how the two drugs work together in HER2-positive breast cancer.
Citazioni salienti
While these results are encouraging, particularly for patients with high tumor burden and hormone receptor-negative disease, they come from a single-arm phase 2 trial. Randomized studies comparing this approach with current standards will be essential before this strategy can be widely adopted.— Dr. Rebecca Alexandra Dent, National Cancer Centre Singapore
Vuoi la storia completa?
Leggi l'originale su The ASCO Post ↗
Health & Medicine